世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
ウイルスおよび非ウイルスベクター製造 - 世界市場シェアとランキング、全体売上高と需要予測 2024-2030Viral and Non Viral Vector Manufacturing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 ウイルスおよび非ウイルス性ベクター製造の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に％のCAGRで2030年までに100万米ドルの再調整された規模になると予測されてい... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリーウイルスおよび非ウイルス性ベクター製造の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に％のCAGRで2030年までに100万米ドルの再調整された規模になると予測されています。ウイルスおよび非ウイルス性ベクター製造の北米市場は、2023年に100万米ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万米ドルに達すると予測されています。 ウイルスおよび非ウイルスベクター製造のアジア太平洋市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万ドルに達するだろう。 ウイルスおよび非ウイルス性ベクター製造のヨーロッパ市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万ドルに達するだろう。 ウイルスおよび非ウイルスベクター製造の世界の主要企業には、ベーリンガーインゲルハイム、キャタレント、富士フイルムホールディングス、ダナハーコーポレーション、レスクリプトバイオテックコーポレーション、ロンザグループAg、メルクケーガン、オックスフォードバイオメディカルPlc、ザルトリウスAgなどが含まれる。2023年には、世界の大手5社が売上高で約 %のシェアを占めている。 レポートの範囲 本レポートは、ウイルス・非ウイルス性ベクター製造の世界市場について、地域別・国別、タイプ別、用途別の分析とともに、総売上高、主要企業の市場シェア、ランキングを中心に包括的に紹介することを目的としています。 ウイルス・非ウイルス性ベクター製造の市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高（百万ドル）で提供します。定量・定性分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、ウイルスおよび非ウイルスベクター製造に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 ベーリンガーインゲルハイム キャタレント 富士フイルムホールディングス ダナハー株式会社 レスクリプト・バイオテック・コーポレーション ロンザグループ メルク・ケーガン オックスフォード・バイオメディカル ザルトリウスAg タカラバイオ サーモフィッシャーサイエンティフィック 無錫オプテック アキュイティズ セラピューティック エボニック エクシード エントス・ファーマシューティカルズ ジェネバントサイエンシズ T&Tサイエンティフィック モデナ キュアバックNv タイプ別セグメント ウイルスベクター 非ウイルス性ベクター 用途別セグメント 遺伝子治療 ワクチン療法 細胞治療 その他 地域別 北米 米国 カナダ 欧州 ドイツ フランス 英国 イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章：報告書のスコープ、世界の総市場規模を紹介。本章ではまた、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章： ウイルス・非ウイルスベクター製造メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析します。 第3章： タイプ別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模や発展可能性を網羅し、読者が様々な市場セグメントにおけるブルーオーシャン市場を見つけるのに役立ちます。 第4章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。 第5章：地域レベルでのウイルスおよび非ウイルスベクター製造の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展見通し、市場スペース、市場規模を紹介しています。 第6章 国別ウイルス・非ウイルス性ベクター製造の収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章：主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 Viral and Non Viral Vector Manufacturing Product Introduction 1.2 Global Viral and Non Viral Vector Manufacturing Market Size Forecast 1.3 Viral and Non Viral Vector Manufacturing Market Trends & Drivers 1.3.1 Viral and Non Viral Vector Manufacturing Industry Trends 1.3.2 Viral and Non Viral Vector Manufacturing Market Drivers & Opportunity 1.3.3 Viral and Non Viral Vector Manufacturing Market Challenges 1.3.4 Viral and Non Viral Vector Manufacturing Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Viral and Non Viral Vector Manufacturing Players Revenue Ranking (2023) 2.2 Global Viral and Non Viral Vector Manufacturing Revenue by Company (2019-2024) 2.3 Key Companies Viral and Non Viral Vector Manufacturing Manufacturing Base Distribution and Headquarters 2.4 Key Companies Viral and Non Viral Vector Manufacturing Product Offered 2.5 Key Companies Time to Begin Mass Production of Viral and Non Viral Vector Manufacturing 2.6 Viral and Non Viral Vector Manufacturing Market Competitive Analysis 2.6.1 Viral and Non Viral Vector Manufacturing Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Viral and Non Viral Vector Manufacturing Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral and Non Viral Vector Manufacturing as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Viral Vector 3.1.2 Non-viral Vector 3.2 Global Viral and Non Viral Vector Manufacturing Sales Value by Type 3.2.1 Global Viral and Non Viral Vector Manufacturing Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Viral and Non Viral Vector Manufacturing Sales Value, by Type (2019-2030) 3.2.3 Global Viral and Non Viral Vector Manufacturing Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Gene Therapy 4.1.2 Vaccinology 4.1.3 Cell Therapy 4.1.4 Others 4.2 Global Viral and Non Viral Vector Manufacturing Sales Value by Application 4.2.1 Global Viral and Non Viral Vector Manufacturing Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Viral and Non Viral Vector Manufacturing Sales Value, by Application (2019-2030) 4.2.3 Global Viral and Non Viral Vector Manufacturing Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Viral and Non Viral Vector Manufacturing Sales Value by Region 5.1.1 Global Viral and Non Viral Vector Manufacturing Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Viral and Non Viral Vector Manufacturing Sales Value by Region (2019-2024) 5.1.3 Global Viral and Non Viral Vector Manufacturing Sales Value by Region (2025-2030) 5.1.4 Global Viral and Non Viral Vector Manufacturing Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 5.2.2 North America Viral and Non Viral Vector Manufacturing Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 5.3.2 Europe Viral and Non Viral Vector Manufacturing Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 5.4.2 Asia Pacific Viral and Non Viral Vector Manufacturing Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 5.5.2 South America Viral and Non Viral Vector Manufacturing Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 5.6.2 Middle East & Africa Viral and Non Viral Vector Manufacturing Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Viral and Non Viral Vector Manufacturing Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Viral and Non Viral Vector Manufacturing Sales Value 6.3 United States 6.3.1 United States Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.3.2 United States Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.4.2 Europe Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.5.2 China Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.5.3 China Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.6.2 Japan Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.7.2 South Korea Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.8.2 Southeast Asia Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.9.2 India Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.9.3 India Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Boehringer Ingelheim 7.1.1 Boehringer Ingelheim Profile 7.1.2 Boehringer Ingelheim Main Business 7.1.3 Boehringer Ingelheim Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.1.4 Boehringer Ingelheim Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.1.5 Boehringer Ingelheim Recent Developments 7.2 Catalent 7.2.1 Catalent Profile 7.2.2 Catalent Main Business 7.2.3 Catalent Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.2.4 Catalent Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.2.5 Catalent Recent Developments 7.3 Fujifilm Holdings Corporation 7.3.1 Fujifilm Holdings Corporation Profile 7.3.2 Fujifilm Holdings Corporation Main Business 7.3.3 Fujifilm Holdings Corporation Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.3.4 Fujifilm Holdings Corporation Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.3.5 Danaher Corporation Recent Developments 7.4 Danaher Corporation 7.4.1 Danaher Corporation Profile 7.4.2 Danaher Corporation Main Business 7.4.3 Danaher Corporation Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.4.4 Danaher Corporation Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.4.5 Danaher Corporation Recent Developments 7.5 Rescript Biotech Corporation 7.5.1 Rescript Biotech Corporation Profile 7.5.2 Rescript Biotech Corporation Main Business 7.5.3 Rescript Biotech Corporation Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.5.4 Rescript Biotech Corporation Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.5.5 Rescript Biotech Corporation Recent Developments 7.6 Lonza Group Ag 7.6.1 Lonza Group Ag Profile 7.6.2 Lonza Group Ag Main Business 7.6.3 Lonza Group Ag Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.6.4 Lonza Group Ag Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.6.5 Lonza Group Ag Recent Developments 7.7 Merck Kagan 7.7.1 Merck Kagan Profile 7.7.2 Merck Kagan Main Business 7.7.3 Merck Kagan Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.7.4 Merck Kagan Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.7.5 Merck Kagan Recent Developments 7.8 Oxford Biomedical Plc 7.8.1 Oxford Biomedical Plc Profile 7.8.2 Oxford Biomedical Plc Main Business 7.8.3 Oxford Biomedical Plc Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.8.4 Oxford Biomedical Plc Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.8.5 Oxford Biomedical Plc Recent Developments 7.9 Sartorius Ag 7.9.1 Sartorius Ag Profile 7.9.2 Sartorius Ag Main Business 7.9.3 Sartorius Ag Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.9.4 Sartorius Ag Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.9.5 Sartorius Ag Recent Developments 7.10 Takara Bio 7.10.1 Takara Bio Profile 7.10.2 Takara Bio Main Business 7.10.3 Takara Bio Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.10.4 Takara Bio Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.10.5 Takara Bio Recent Developments 7.11 Thermo Fisher Scientific 7.11.1 Thermo Fisher Scientific Profile 7.11.2 Thermo Fisher Scientific Main Business 7.11.3 Thermo Fisher Scientific Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.11.4 Thermo Fisher Scientific Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.11.5 Thermo Fisher Scientific Recent Developments 7.12 Wuxi Optec 7.12.1 Wuxi Optec Profile 7.12.2 Wuxi Optec Main Business 7.12.3 Wuxi Optec Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.12.4 Wuxi Optec Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.12.5 Wuxi Optec Recent Developments 7.13 Acuities Therapeutic 7.13.1 Acuities Therapeutic Profile 7.13.2 Acuities Therapeutic Main Business 7.13.3 Acuities Therapeutic Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.13.4 Acuities Therapeutic Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.13.5 Acuities Therapeutic Recent Developments 7.14 Evonik Industries Ag 7.14.1 Evonik Industries Ag Profile 7.14.2 Evonik Industries Ag Main Business 7.14.3 Evonik Industries Ag Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.14.4 Evonik Industries Ag Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.14.5 Evonik Industries Ag Recent Developments 7.15 Exiled 7.15.1 Exiled Profile 7.15.2 Exiled Main Business 7.15.3 Exiled Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.15.4 Exiled Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.15.5 Exiled Recent Developments 7.16 Entos Pharmaceuticals 7.16.1 Entos Pharmaceuticals Profile 7.16.2 Entos Pharmaceuticals Main Business 7.16.3 Entos Pharmaceuticals Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.16.4 Entos Pharmaceuticals Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.16.5 Entos Pharmaceuticals Recent Developments 7.17 Genevant Sciences Gmbh 7.17.1 Genevant Sciences Gmbh Profile 7.17.2 Genevant Sciences Gmbh Main Business 7.17.3 Genevant Sciences Gmbh Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.17.4 Genevant Sciences Gmbh Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.17.5 Genevant Sciences Gmbh Recent Developments 7.18 T&T Scientific Corporation 7.18.1 T&T Scientific Corporation Profile 7.18.2 T&T Scientific Corporation Main Business 7.18.3 T&T Scientific Corporation Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.18.4 T&T Scientific Corporation Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.18.5 T&T Scientific Corporation Recent Developments 7.19 Moderna 7.19.1 Moderna Profile 7.19.2 Moderna Main Business 7.19.3 Moderna Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.19.4 Moderna Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.19.5 Moderna Recent Developments 7.20 Curevac Nv 7.20.1 Curevac Nv Profile 7.20.2 Curevac Nv Main Business 7.20.3 Curevac Nv Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.20.4 Curevac Nv Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.20.5 Curevac Nv Recent Developments 8 Industry Chain Analysis 8.1 Viral and Non Viral Vector Manufacturing Industrial Chain 8.2 Viral and Non Viral Vector Manufacturing Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Viral and Non Viral Vector Manufacturing Sales Model 8.5.2 Sales Channel 8.5.3 Viral and Non Viral Vector Manufacturing Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Viral and Non Viral Vector Manufacturing was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030. Table of Contents1 Market Overview1.1 Viral and Non Viral Vector Manufacturing Product Introduction 1.2 Global Viral and Non Viral Vector Manufacturing Market Size Forecast 1.3 Viral and Non Viral Vector Manufacturing Market Trends & Drivers 1.3.1 Viral and Non Viral Vector Manufacturing Industry Trends 1.3.2 Viral and Non Viral Vector Manufacturing Market Drivers & Opportunity 1.3.3 Viral and Non Viral Vector Manufacturing Market Challenges 1.3.4 Viral and Non Viral Vector Manufacturing Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Viral and Non Viral Vector Manufacturing Players Revenue Ranking (2023) 2.2 Global Viral and Non Viral Vector Manufacturing Revenue by Company (2019-2024) 2.3 Key Companies Viral and Non Viral Vector Manufacturing Manufacturing Base Distribution and Headquarters 2.4 Key Companies Viral and Non Viral Vector Manufacturing Product Offered 2.5 Key Companies Time to Begin Mass Production of Viral and Non Viral Vector Manufacturing 2.6 Viral and Non Viral Vector Manufacturing Market Competitive Analysis 2.6.1 Viral and Non Viral Vector Manufacturing Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Viral and Non Viral Vector Manufacturing Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral and Non Viral Vector Manufacturing as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Viral Vector 3.1.2 Non-viral Vector 3.2 Global Viral and Non Viral Vector Manufacturing Sales Value by Type 3.2.1 Global Viral and Non Viral Vector Manufacturing Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Viral and Non Viral Vector Manufacturing Sales Value, by Type (2019-2030) 3.2.3 Global Viral and Non Viral Vector Manufacturing Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Gene Therapy 4.1.2 Vaccinology 4.1.3 Cell Therapy 4.1.4 Others 4.2 Global Viral and Non Viral Vector Manufacturing Sales Value by Application 4.2.1 Global Viral and Non Viral Vector Manufacturing Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Viral and Non Viral Vector Manufacturing Sales Value, by Application (2019-2030) 4.2.3 Global Viral and Non Viral Vector Manufacturing Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Viral and Non Viral Vector Manufacturing Sales Value by Region 5.1.1 Global Viral and Non Viral Vector Manufacturing Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Viral and Non Viral Vector Manufacturing Sales Value by Region (2019-2024) 5.1.3 Global Viral and Non Viral Vector Manufacturing Sales Value by Region (2025-2030) 5.1.4 Global Viral and Non Viral Vector Manufacturing Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 5.2.2 North America Viral and Non Viral Vector Manufacturing Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 5.3.2 Europe Viral and Non Viral Vector Manufacturing Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 5.4.2 Asia Pacific Viral and Non Viral Vector Manufacturing Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 5.5.2 South America Viral and Non Viral Vector Manufacturing Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 5.6.2 Middle East & Africa Viral and Non Viral Vector Manufacturing Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Viral and Non Viral Vector Manufacturing Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Viral and Non Viral Vector Manufacturing Sales Value 6.3 United States 6.3.1 United States Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.3.2 United States Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.4.2 Europe Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.5.2 China Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.5.3 China Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.6.2 Japan Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.7.2 South Korea Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.8.2 Southeast Asia Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Viral and Non Viral Vector Manufacturing Sales Value, 2019-2030 6.9.2 India Viral and Non Viral Vector Manufacturing Sales Value by Type (%), 2023 VS 2030 6.9.3 India Viral and Non Viral Vector Manufacturing Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Boehringer Ingelheim 7.1.1 Boehringer Ingelheim Profile 7.1.2 Boehringer Ingelheim Main Business 7.1.3 Boehringer Ingelheim Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.1.4 Boehringer Ingelheim Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.1.5 Boehringer Ingelheim Recent Developments 7.2 Catalent 7.2.1 Catalent Profile 7.2.2 Catalent Main Business 7.2.3 Catalent Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.2.4 Catalent Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.2.5 Catalent Recent Developments 7.3 Fujifilm Holdings Corporation 7.3.1 Fujifilm Holdings Corporation Profile 7.3.2 Fujifilm Holdings Corporation Main Business 7.3.3 Fujifilm Holdings Corporation Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.3.4 Fujifilm Holdings Corporation Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.3.5 Danaher Corporation Recent Developments 7.4 Danaher Corporation 7.4.1 Danaher Corporation Profile 7.4.2 Danaher Corporation Main Business 7.4.3 Danaher Corporation Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.4.4 Danaher Corporation Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.4.5 Danaher Corporation Recent Developments 7.5 Rescript Biotech Corporation 7.5.1 Rescript Biotech Corporation Profile 7.5.2 Rescript Biotech Corporation Main Business 7.5.3 Rescript Biotech Corporation Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.5.4 Rescript Biotech Corporation Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.5.5 Rescript Biotech Corporation Recent Developments 7.6 Lonza Group Ag 7.6.1 Lonza Group Ag Profile 7.6.2 Lonza Group Ag Main Business 7.6.3 Lonza Group Ag Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.6.4 Lonza Group Ag Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.6.5 Lonza Group Ag Recent Developments 7.7 Merck Kagan 7.7.1 Merck Kagan Profile 7.7.2 Merck Kagan Main Business 7.7.3 Merck Kagan Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.7.4 Merck Kagan Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.7.5 Merck Kagan Recent Developments 7.8 Oxford Biomedical Plc 7.8.1 Oxford Biomedical Plc Profile 7.8.2 Oxford Biomedical Plc Main Business 7.8.3 Oxford Biomedical Plc Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.8.4 Oxford Biomedical Plc Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.8.5 Oxford Biomedical Plc Recent Developments 7.9 Sartorius Ag 7.9.1 Sartorius Ag Profile 7.9.2 Sartorius Ag Main Business 7.9.3 Sartorius Ag Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.9.4 Sartorius Ag Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.9.5 Sartorius Ag Recent Developments 7.10 Takara Bio 7.10.1 Takara Bio Profile 7.10.2 Takara Bio Main Business 7.10.3 Takara Bio Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.10.4 Takara Bio Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.10.5 Takara Bio Recent Developments 7.11 Thermo Fisher Scientific 7.11.1 Thermo Fisher Scientific Profile 7.11.2 Thermo Fisher Scientific Main Business 7.11.3 Thermo Fisher Scientific Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.11.4 Thermo Fisher Scientific Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.11.5 Thermo Fisher Scientific Recent Developments 7.12 Wuxi Optec 7.12.1 Wuxi Optec Profile 7.12.2 Wuxi Optec Main Business 7.12.3 Wuxi Optec Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.12.4 Wuxi Optec Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.12.5 Wuxi Optec Recent Developments 7.13 Acuities Therapeutic 7.13.1 Acuities Therapeutic Profile 7.13.2 Acuities Therapeutic Main Business 7.13.3 Acuities Therapeutic Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.13.4 Acuities Therapeutic Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.13.5 Acuities Therapeutic Recent Developments 7.14 Evonik Industries Ag 7.14.1 Evonik Industries Ag Profile 7.14.2 Evonik Industries Ag Main Business 7.14.3 Evonik Industries Ag Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.14.4 Evonik Industries Ag Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.14.5 Evonik Industries Ag Recent Developments 7.15 Exiled 7.15.1 Exiled Profile 7.15.2 Exiled Main Business 7.15.3 Exiled Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.15.4 Exiled Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.15.5 Exiled Recent Developments 7.16 Entos Pharmaceuticals 7.16.1 Entos Pharmaceuticals Profile 7.16.2 Entos Pharmaceuticals Main Business 7.16.3 Entos Pharmaceuticals Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.16.4 Entos Pharmaceuticals Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.16.5 Entos Pharmaceuticals Recent Developments 7.17 Genevant Sciences Gmbh 7.17.1 Genevant Sciences Gmbh Profile 7.17.2 Genevant Sciences Gmbh Main Business 7.17.3 Genevant Sciences Gmbh Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.17.4 Genevant Sciences Gmbh Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.17.5 Genevant Sciences Gmbh Recent Developments 7.18 T&T Scientific Corporation 7.18.1 T&T Scientific Corporation Profile 7.18.2 T&T Scientific Corporation Main Business 7.18.3 T&T Scientific Corporation Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.18.4 T&T Scientific Corporation Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.18.5 T&T Scientific Corporation Recent Developments 7.19 Moderna 7.19.1 Moderna Profile 7.19.2 Moderna Main Business 7.19.3 Moderna Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.19.4 Moderna Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.19.5 Moderna Recent Developments 7.20 Curevac Nv 7.20.1 Curevac Nv Profile 7.20.2 Curevac Nv Main Business 7.20.3 Curevac Nv Viral and Non Viral Vector Manufacturing Products, Services and Solutions 7.20.4 Curevac Nv Viral and Non Viral Vector Manufacturing Revenue (US$ Million) & (2019-2024) 7.20.5 Curevac Nv Recent Developments 8 Industry Chain Analysis 8.1 Viral and Non Viral Vector Manufacturing Industrial Chain 8.2 Viral and Non Viral Vector Manufacturing Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Viral and Non Viral Vector Manufacturing Sales Model 8.5.2 Sales Channel 8.5.3 Viral and Non Viral Vector Manufacturing Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療）の最新刊レポート
QYResearch社の医療分野での最新刊レポート
本レポートと同じKEY WORD（）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/19 10:26 155.48 円 165.11 円 199.74 円 |